LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RNAC
Cartesian Therapeutics, Inc.
There isn't enough reported data to score RNAC yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RNAC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
RNAC's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RNAC PE Valuation
RNAC has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RNAC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RNAC's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RNAC in the latest year-over-year earnings comparison.
RNAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2021 | -$20.70 | +$12.90 |
| Q4 2020 | -$20.40 | +$16.20 |
RNAC is still losing money, but far less than before: $4.84 per share over the past year, against $56.10 at its worst in early 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RNAC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
RNAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $78K | -93% |
| Q3 2025 | $452K | +17% |
| Q2 2025 | $298K | -99% |
| Q1 2025 | $1.1M | -81% |
| Q3 2024 | $387K | -94% |
| Q2 2024 | $33.4M | +537% |
| Q1 2024 | $5.8M | -1.7% |
| Q4 2023 | $8.3M | -51% |
RNAC's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -33973% | -31983 points |
| Q4 2025 | -8304% | N/A |
| Q3 2025 | -4661% | -119 points |
| Q2 2025 | -7319% | -7360 points |
| Q1 2025 | -1990% | -1761 points |
| Q3 2024 | -4541% | -4342 points |
| Q2 2024 | 41% | +396 points |
| Q1 2024 | -229% | +81 points |
RNAC's operating margin was −33973% last quarter, down 31983 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RNAC on cash generation, producing positive trailing cash flow while its opponent burns cash.
RNAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.2M | -$11.3M |
| Q2 2026 | -$21.4M | -$1.2M |
| Q1 2026 | -$22.2M | +$2M |
| Q4 2025 | -$18.2M | -$10.5M |
| Q3 2025 | -$16.9M | -325% |
| Q2 2025 | -$20.1M | -$4.1M |
| Q1 2025 | -$24.2M | -$7.7M |
| Q4 2024 | -$7.7M | +$15.6M |
RNAC has burned cash in almost every quarter: −$90M over the past year, against −$69M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RNAC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RNAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +448K shares |
| 1 year | +17% | +4.3M shares |
| 3 years | +493% | +25.2M shares |
| 5 years | +798% | +26.9M shares |
RNAC has 30M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RNAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -7.0x | Net Cash |
| Q3 2022 | -4.1x | Net Cash |
| Q2 2022 | -5.1x | Net Cash |
| Q1 2022 | -8.1x | Net Cash |
RNAC has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RNAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 16.1 | Oversold |
RNAC's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RNAC PE vs Healthcare Sector
| Metric | RNAC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RNAC has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RNAC on trend strength, trading above more of its moving averages.
RNAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.83 | 6.9% below |
| 20 week MA | $8.07 | 21% below |
| 50 week MA | $7.57 | 16% below |
| 100 week MA | $10.1 | 37% below |
| 200 week MA | $19.2 | 67% below |
RNAC is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RNAC on returns for 2026, with the stronger performance.
RNAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.7 | $98.1 | +43% |
| 2021 | $98.1 | $107.1 | +9.2% |
| 2022 | $107.1 | $29.4 | -73% |
| 2023 | $29.4 | $20.7 | -30% |
| 2024 | $20.7 | $19.8 | -4.3% |
| 2025 | $19.8 | $6.68 | -66% |
| 2026 YTD | $6.68 | $6.36 | -4.8% |
RNAC has finished four years in a row lower, and it's down 4.8% so far in 2026.